Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:49 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 7,882 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Non intervention study Clear all

Conditions: Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Computed Tomography, Osimertinib, Positron Emission Tomography, Stereotactic Body Radiation Therapy, Survey Administration; Procedure · Drug · Radiation + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Duarte, California • New Haven, Connecticut

Conditions: Autism Spectrum Disorder
Interventions: Stimulus-stimulus pairing, Vocal recorder; Behavioral · Other
Lead sponsor: Emory University; Other
Eligibility: 24 Months to 47 Months
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Exercise Endurance
Interventions: Probiotic, Placebo; Dietary Supplement
Lead sponsor: Lallemand Health Solutions; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Mental Health and General Well-being
Interventions: Miracle of Mind meditation, Neutral audio learning task; Behavioral
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 40 Years
Enrollment: 354 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Insomnia Disorder
Interventions: Cognitive Behavioral Therapy for Insomnia (CBT-I), Passive Body Heating (PBH); Behavioral · Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Physical Inactivity
Interventions: Creatine Monohydrate, Blood Flow Restriction, Exercise; Dietary Supplement · Device · Other
Lead sponsor: University of Central Florida; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Distress, Emotional
Interventions: Expressive writing in response to vignette, Expressive writing about events of the day, Letter of Gratitude; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Advanced Malignant Solid Neoplasm, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions: Support Group Therapy, Symptom Management Service (SMS) Consultation, Quality of Life (QOL) Questionnaires, Interview; Behavioral · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV, Depression, HIV Infections
Interventions: COMB - Combination Cognitive Behavioral Therapy and Medication Management, TAU - Treatment as Usual; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 16 Years to 24 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 4
States / cities: Tampa, Florida • The Bronx, New York • Philadelphia, Pennsylvania + 1 more

Conditions: Surgical Procedure, Unspecified, Orthopedic Disorder
Interventions: Standardized instructions, Conventional instructions; Other
Lead sponsor: Giorgio Veneziano; Other
Eligibility: Up to 20 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Diabetes
Interventions: FreeStyle Navigator II Continuous Glucose Monitoring System; Device
Lead sponsor: Abbott Diabetes Care; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Atlanta, Georgia • Santa Fe, New Mexico

Conditions: Parkinson Disease
Interventions: Multimodal Exercise Program with Gamification; Other
Lead sponsor: California State University, Northridge; Other
Eligibility: 40 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Ventura, California

Conditions: Pain
Interventions: Paracervical Nerve Block, Sham Paracervical Block; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 14 Years to 22 Years · Female only
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Philadelphia, Pennsylvania

Conditions: Health Behavior, Adolescent Behavior, Motivation
Interventions: Intervention Group (motivational website, activity meter), Active Control (active video game, activity meter), Passive Control (activity meter); Behavioral · Other
Lead sponsor: HopeLab Foundation; Other
Eligibility: 11 Years to 14 Years
Enrollment: 182 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 3
States / cities: Mountain View, California • Vista, California • Morgantown, West Virginia

Conditions: Opioid Pain Medication
Interventions: Tranexamic acid, Aminocaproic acid, Recombinant Human Thrombin, Lidocaine Hydrochloride with Epinephrine, Bupivacaine Hydrochloride with Epinephrine; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 99 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes Mellitus, Type 2
Interventions: Carbohydrate-restricted diet, Mindfulness; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Congenital Adrenal Hyperplasia (CAH)
Interventions: Fludrocortisone, Hydrocortisone, Letrozole, Flutamide, Testolactone; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 2 Years to 18 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Spinal Cord Injuries
Interventions: Enhanced Medical Rehabilitation (EMR); Behavioral
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Alcoholism, Alcohol Dependence, Posttraumatic Stress Disorder
Interventions: Aprepitant, Placebo; Drug
Lead sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA); NIH
Eligibility: 21 Years to 50 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hemophilia A
Interventions: Not listed
Lead sponsor: Octapharma; Industry
Eligibility: Male only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 5
States / cities: Gainesville, Florida • Miami, Florida • New Orleans, Louisiana + 2 more

Conditions: Multiple Myeloma, Lymphoma, Non-Hodgkin
Interventions: XM02 Filgrastim, Filgrastim, Apheresis, Plerixafor, Stem Cell Transplant; Drug · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Myotonic Dystrophy Type 2, Myotonic Dystrophy Type 1
Interventions: Non-interventional study; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 30 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Painful Diabetic Neuropathy (PDN), Diabetic Nephropathies
Interventions: Cognitive Behavioral Therapy (CBT), Oral Medication, Topical Medication; Device · Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 23
States / cities: Stanford, California • Jacksonville, Florida • Chicago, Illinois + 17 more

Conditions: LCA5
Interventions: AAV8.hLCA5; Biological
Lead sponsor: Opus Genetics, Inc; Industry
Eligibility: 4 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Dallas, Texas

Search by objective public record fields.

Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma

Stimulus-Stimulus Pairing Study

Impact of Probiotic Supplementation on Exercise Endurance Among Non-elite Athletes

Effect of a Brief Daily Digital Meditation on Well-Being in US Young Adults (BEGIN II)

Optimizing an Integrated Mind and Body Treatment for Insomnia: The SLEEPS Study 2

Blood Flow Restriction and Creatine Supplementation in Women

Expressive Writing Intervention Study

Integrative Palliative Care/Psycho-Oncology Telehealth Intervention in Patients With Advanced Cancer

Treatment for Depression Among HIV-Infected Youth

Opioid Consumption After Knee Arthroscopy

Navigator II Continuous Glucose Monitor Home Use Study

Title: A Multimodal Exercise Program With Gamification for Parkinson Disease (MEP+G)

Study of Pain Control With Hormonal IUS Insertion

Accelerometer-linked Online Intervention to Promote Physical Activity in Adolescents

Evaluating Postoperative Non-Opioid Pain Management Utilizing Local Anesthetics Coupled With Modulated Coagulation

Delish Study: Diabetes Education to Lower Insulin, Sugars, and Hunger

Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia

Enhanced Medical Rehabilitation for Spinal Cord Injury

The Effect of NK1R Antagonism on Alcohol Craving and PTSD Symptoms in Alcohol Dependent Patients With PTSD

Non-interventional Post-authorisation Study to Document the Immunogenicity, Safety, and Efficacy of NUWIQ

Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma

Brain Structure and Clinical Endpoints in Myotonic Dystrophy Type 2

Modality Choice Before and After Failure for the Treatment of Painful Diabetic Neuropathy

Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD) and Non-interventional Arm With Untreated Patients